Refractory Chronic Cough Therapeutics Market
Number of pages: 100 | Report Format: PDF | Published date: November 15, 2022
Historical Years – 2020 | Base Year – 2021 | Forecasted Years – 2022-2030
|
Report Attribute |
Details |
|
Market size value in 2021 |
US$ 8.65 billion |
|
Revenue forecast in 2030 |
US$ 11.99 billion |
|
Growth Rate |
CAGR of 3.7% from 2022 to 2030 |
|
Base year for estimation |
2021 |
|
Forecast period |
2022-2030 |
|
Segments covered |
drug class, distribution channel, and region. |
|
Regional scope |
North America, Europe, Asia Pacific, and the Rest of the World (ROW) |
The global refractory chronic cough therapeutics market was pegged at US$ 8.65 billion in 2021 and is expected to witness a CAGR of 3.7% during the forecast period.
Market Fundamentals
Chronic cough is widely defined as a cough of greater than 8 weeks duration and is often due to a treatable underlying cause, such as upper airway cough syndrome (postnasal drip syndrome; rhinitis); asthma, and non-asthmatic eosinophilic bronchitis; gastroesophageal reflux disease (GERD). Chronic refractory cough (CRC)/refractory chronic cough is defined as a cough that persists despite guideline-based treatment. It is seen in 20-46% of patients presenting to specialist cough clinics and it has a substantial impact on quality of life and healthcare utilization. Unfortunately, in many situations, patients continue to experience CRC despite following published guidelines for diagnosis and treatment.
[5654645]
Market Dynamic
Asthma, acid reflux and postnasal drip are a few of the underlying conditions that contribute to the rising prevalence of chronic cough. Which in turn, is responsible for the growth of the global refractory chronic cough therapeutics market. The market would grow because of increased global healthcare spending and disease awareness, allowing pharmaceutical companies to boost their market share. The focus of the medicines currently under development is on cutting-edge methods for treating or bettering the illness state.
However, the lack of approved therapy for refractory chronic cough is one of the major challenges for the growth of the therapeutics market.
Market Ecosystem
The global refractory chronic cough therapeutics market has been analyzed from three perspectives: drug class, distribution channel, and region.
Refractory Chronic Cough Therapeutics Market by Drug Class
[23433545]
Based on drug class, the global refractory chronic cough therapeutics market has been divided into, neuromodulators, proton pump inhibitors, inhaled corticosteroids, and others. Neuromodulators include opiates (morphine, codeine, tramadol, etc.), gabapentin, pregabalin, morphine, amitriptyline, and baclofen, which act on the heightened neural sensitization that is involved in the pathogenesis of refractory chronic cough. Among the available pharmacologic therapies, codeine is one of the most used drugs in the refractory chronic cough treatment. Morphine, gabapentin, and tramadol are also among the frequently used therapies to provide relief from a chronic cough.
Refractory Chronic Cough Therapeutics Market by Distribution Channel
Based on the distribution channel, the global refractory chronic cough therapeutics market is subdivided into hospital pharmacies, retail pharmacies, and others. The hospital pharmacy segment dominates the global refractory chronic cough therapeutics market. This is attributed to the ease of availability of the drugs and increased diagnostics in the hospitals.
Refractory Chronic Cough Therapeutics Market by Region
Based on region, the global refractory chronic cough therapeutics market has been segmented into North America, Europe, Asia Pacific, and the Rest of the World. North America holds the majority of the share of the global refractory chronic cough therapeutics market. The growth of the market in the region is characterized by rising disease prevalence and need for treatment, together with rising disease diagnosis and adoption of cutting-edge therapies. The area holds a significant share of the global market due to these reasons, as well as the patient population's increased healthcare expenditures toward novel treatment alternatives and the presence of major businesses with their pipeline candidates and planned launches.
Competitive Landscape
Some of the prominent players operating in the global refractory chronic cough therapeutics market are: -
Strategic Developments
The global refractory chronic cough therapeutics market is expected to grow at a CAGR of 3.7% in the forecast period.
Merck & Co., Bayer AG, etc. are a few key players in the global refractory chronic cough therapeutics market.
The neuromodulators segment dominates the global refractory chronic cough therapeutics market.
Asia Pacific region is expected to witness the highest global refractory chronic cough therapeutics market growth in the forecast period.
*Insights on financial permanence are subject to the availability of information in the public domain